Katherine Anne Delaria

Title: Katherine Anne Delaria: Innovator in Antibody-Drug Conjugates

Introduction

Katherine Anne Delaria is a prominent inventor based in Walnut Creek, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. Her innovative work focuses on enhancing the efficacy of cancer treatments through advanced drug delivery systems.

Latest Patents

Katherine holds 1 patent for her invention titled "Antibody-drug conjugates with high drug loading." This invention provides transglutaminase-mediated antibody-drug conjugates with a high antibody-drug ratio (DAR). The conjugates comprise glutamine-containing tags, endogenous glutamines, and amine donor agents, wherein the DAR is at least about 5. The invention also outlines methods for making and using these higher drug-loaded antibody-drug conjugates, which have the potential to improve therapeutic outcomes in cancer treatment.

Career Highlights

Throughout her career, Katherine has worked with notable companies in the biotechnology sector, including Rinat Neuroscience Corporation and Pfizer Corporation. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in the field of drug delivery systems.

Collaborations

Katherine has collaborated with esteemed colleagues such as Pavel Strop and Magdalena Grazyna Dorywalska. These partnerships have further enriched her research and innovation efforts in the biotechnology landscape.

Conclusion

Katherine Anne Delaria's work in antibody-drug conjugates exemplifies her commitment to advancing medical science and improving patient care. Her innovative contributions continue to shape the future of cancer treatment.